Sigrid Therapeutics
Quotes
Share:
Subscribe:
news.cision.com
/
Sigrid Therapeutics
/
Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control
/
Pietiläinen Kirsi
1 of 3
Pietiläinen Kirsi
Tue, Apr 30, 2024 08:30 CET
Low resolution
Medium resolution
Original resolution
Subscribe
Related Releases
Sigrid Therapeutics Completes Enrollment in SHINE to Evaluate SiPore21® Gel for Sustained Blood Sugar and Weight Management
Tue, Jul 30, 2024 08:30 CET
